HomePharmacologyAntiplatelet

Antiplatelet

DAPT Substudy: Score to Personalize Optimal Dual Antiaggregation Therapy Duration

Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the...

PEGASUS-TIMI 54 Subanalysis: Discontinuation of Ticagrelor Mostly Due to Dyspnea or Bleeding

Original Title: Long-term tolerability of ticagrelor for secondary prevention: insights from PEGASUS-TIMI 54 trial. Presenter: Bonaca MP. The higher...

Net clinical benefit of bivalirudin in STEMI patients

Original title: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous...

Less Bleeding at the Expense of a Higher Risk of Acute Thrombosis with Bivalirudin

Original title: Bivalirudin versus heparin in patients treated with percutaneous coronary Intervention: a meta-analysis of randomised trials. Reference: Salvatore Cassese...

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Original title: Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes...

Decreased bleeding with radial access leaves little to bivalirudin for additional benefit

Original title: Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. Reference: Sciahbasi...

Bivalirudin, effective in the pre-hospitalization phase of infarction

Original title: Bivalirudin Started during Emergency Transport for Primary PCI. Reference: Philippe G. Steg, et;al. NEJM 2013; Octubre 30:1-11Primary PCI...

Low cardiac mortality with bivalirudin beyond the reduction in major bleeding

Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg...